Aprea's APR-1051 Shows Partial Responses in Endometrial Cancer, ATRN-119 Advances; Q1 Loss $0.22
APRE sits 61% above its 52-week low of $0.548.
Summary
Aprea Therapeutics announced positive clinical progress for its pipeline candidates, with APR-1051 showing partial responses in PPP2R1A-mutated endometrial cancer and ATRN-119 establishing its Phase 2 dose. The company also reported its Q1 adjusted loss of $0.22 per share and reiterated a cash runway into Q1 2028. While the Q1 financial results and cash runway were largely disclosed in the 8-K and 10-Q filings on May 13th, the specific clinical data for APR-1051 and ATRN-119 are new and highly material for this micro-cap biotech. Positive clinical trial data, especially partial responses, can significantly impact investor perception and valuation. Traders will be watching for further clinical readouts and the planned IND studies for APR-1602 in late 2026.
At the time of this announcement, APRE was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $0.55 to $2.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.